Journal article
Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study
Abstract
IntroductionDenosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodeling, and an increased risk of fracture. We evaluated the effect of low dose denosumab (30 mg every 6 months) on the prevention of bone loss following a switch from standard dose (60 mg of …
Authors
Khan AA; AbuAlrob H; M’Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S
Journal
Endocrine, Vol. 80, No. 3, pp. 647–657
Publisher
Springer Nature
Publication Date
June 2023
DOI
10.1007/s12020-022-03230-5
ISSN
1355-008X